Last reviewed · How we verify

Azad Pharma AG — Portfolio Competitive Intelligence Brief

Azad Pharma AG pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Venofer® Venofer® marketed Iron replacement agent Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. American Regent, Inc. · 1 shared drug class
  4. CN NGANOU-GNINDJIO, MD, MSc · 1 shared drug class
  5. China-Japan Friendship Hospital · 1 shared drug class
  6. Hallym University Medical Center · 1 shared drug class
  7. J. Uriach and Company · 1 shared drug class
  8. JW Pharmaceutical · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azad Pharma AG:

Cite this brief

Drug Landscape (2026). Azad Pharma AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azad-pharma-ag. Accessed 2026-05-14.

Related